Preview this article 1 min Biogen is buying a Boston-area biotech that already has two approved drugs to drive short-term and ...
While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...
Biotechnology company Lipella Pharmaceuticals Inc. files for Chapter 11 bankruptcy months after facing Nasdaq delisting.
We explore what allosteric modulators are, their benefits and drawbacks, and which candidates are currently advancing through ...
LIXTE Biotechnology Holdings, Inc. ('LIXTE” or the 'Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech ...
Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ...
Incubate Founder and Executive Director John Stanford spent a busy day on Capitol Hill this week making the case that the ...
On March 30, 2026, Viva Biotech Holdings ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that for the Group's revenue amounted to RMB1,729.4 million during the Reporting ...
Mantis takes disparate sources of data to make synthetic datasets that can be used to build so-called "digital twins" of the ...
Tivic Health Systems is developing immune‑modulating therapies for conditions, such as radiation exposure, while expanding ...
The FDA has warned a biotech company about claims that its bladder cancer drug could treat and prevent multiple types of cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results